general
Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022
SHANGHAI and HONG KONG, Sept. 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies,...
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
What to Know About the Execution Attempt of Christa Pike
The New York Times
5 Takeaways From the Debate for California Governor
The New York Times
Who Is Captain Smit Machchhar, the Pilot Hailed as a Hero After FlyDubai Cockpit Stabbing?
The New York Times
Helicopter crashes off Catalina Island coast, rescue efforts underway
CBS News
The Cornell Rape Investigation: Five Takeaways
The New York Times